Chemical Compound
Bufexamac; 4-Butoxy-N-hydroxy-benzeneacetamide; 2-(p-Butoxyphenyl)-acetohydroxamic acid; 2-(p-Butoxyphenyl)acetohydroxamic acid; 4-Butoxyphenylacethydroxamic acid; Anderm; Bufexamic acid; CP 1044J3; Droxarol; Droxaryl; Feximac; Flogocid; Flogocid N plasti; Flogocid N plastigel; Malipuran; Mofenar; Norfemac; Parfenac; Parfenal; p-Butoxyphenylacethydroxamic acid; p-Butoxyphenylacetohydroxamic acid
CAS Registry Number
2438-72-4
Primary record
Bufexamac; 4-Butoxy-N-hydroxy-benzeneacetamide; 2-(p-Butoxyphenyl)-acetohydroxamic acid; 2-(p-Butoxyphenyl)acetohydroxamic acid; 4-Butoxyphenylacethydroxamic acid; Anderm; Bufexamic acid; CP 1044J3; Droxarol; Droxaryl; Feximac; Flogocid; Flogocid N plasti; Flogocid N plastigel; Malipuran; Mofenar; Norfemac; Parfenac; Parfenal; p-Butoxyphenylacethydroxamic acid; p-Butoxyphenylacetohydroxamic acid
- 库存
- 4,684 克
- 纯度
- 98.4 %
- CAS
- 2438-72-4
化合物标识与属性
- CAS
- 2438-72-4
- PubChem CID
- 2466
- SMILES
- CCCCOC1=CC=C(C=C1)CC(=O)NO
- Canonical SMILES
- CCCCOc1ccc(CC(=O)NO)cc1
名称与同义词
- bufexamac
- Bufexamic acid
- Parfenac
- Anderm
- Droxaryl
- Paraderm
- Parfenal
- Feximac
- Mofenar
- 2438-72-4
- Bufexamaco
- Malipuran
- Flogicid
- Norfemac
- Bufexamacum
- 2-(4-Butoxyphenyl)-N-hydroxyacetamide
- Droxarol
- Bufessamac
- Flogocid N plastigel
- bufexamicacid
- duradermal
- Allergipuran
- Bufederm
- Rublasone
- Salibedol
- Anhoril
- Entymac
- Derxam
- Hifmac
- Windol
- Bufal
- Jomax
- Bufexamacratiopharm
- Bufessamac [DCIT]
- Bufexamac CRS
- Bufexamac ratiopharm
- 4-Butoxy-N-hydroxybenzeneacetamide
- p-Butoxyphenylacetohydroxamic acid
- 4-Butoxyphenylacetohydroxamic acid
- Bufexamac-ratiopharm
- Prestwick_676
- Anderm (TN)
- Bufexamacum [INN-Latin]
- Bufexamac (Standard)
- Bufexamaco [INN-Spanish]
- Acide p-butoxyphenylacethydroxamique
- Spectrum_001754
- Bufexamac (JAN/INN)
- 2-(p-Butoxyphenyl)-acetohydroxamic acid
- BUFEXAMAC [INN]
- BUFEXAMAC [JAN]
- CP 1044 J3
- DTXSID7045368
- AC1L1DQQ
- AC1Q2XHW
- AC1Q5QCV
- C12H17NO3
- cp1044j3
- Opera_ID_1503
- Prestwick0_000243
- Prestwick1_000243
- Prestwick2_000243
- Prestwick3_000243
- RefChem:570466
- Spectrum2_001457
- Spectrum3_000938
- Spectrum4_001037
- Spectrum5_001117
- 2-(p-Butoxyphenyl)acetohydroxamic acid
- Benzeneacetamide, 4-butoxy-N-hydroxy-
- MXJWRABVEGLYDG-UHFFFAOYSA-N
- p-Butoxyphenylacethydroxamic Acid
- BUFEXAMAC [MART.]
- CHEBI:31317
- CHEMBL94394
- D02HXS
- Epitope ID:180855
- Bufexamac [INN:BAN:DCF:JAN]
- UNII-4T3C38J78L
- BUFEXAMAC [WHO-DD]
- cid_2466
- MLS000028409
- 4T3C38J78L
- REGID_for_CID_2466
- SCHEMBL25215
- BSPBio_000026
- DTXCID5025368
- KBioGR_001593
- KBioSS_002234
- p Butoxyphenylacethydroxamic Acid
- cp1044
- MLS001148632
- 2-(4-butoxyphenyl)acetohydroxamic acid
- Bufexamac, analytical standard
- CP-1044-J3
- DivK1c_000108
- NSC-758153
- SPECTRUM1502003
- CP 1044
- EINECS 219-451-1
- SPBio_001353
- SPBio_002245
- MFCD00078936
- BPBio1_000030
- GTPL7498
- ML392
- orb1310218
- orb3025831
- 4-butoxyphenylacetohydroxamicacid
- BUFEXAMAC [EP IMPURITY]
- BUFEXAMAC [EP MONOGRAPH]
- SCHEMBL21409744
- BENZYLCHLOROACETYLCARBAMATE
- CTK8F8354
- ERK5-6B03
- HMS500F10
- HY-B0494R
- KBio1_000108
- KBio2_002234
- KBio2_004802
- KBio2_007370
- KBio3_001976
- 2-(4-butoxyphenyl)ethanehydroxamic acid
- acidep-butoxyphenylacethydroxamique
- BRN 2646848
- Bufexamac [BAN:DCF:INN:JAN]
- CID2466
- M01AB17
- M02AA09
- NINDS_000108
- s3023
- 4-butoxy-n-hydroxy-benzeneacetamid
- 4-Butoxybenzeneacetohydroxamic acid
- GLXC-05312
- HMS1568B08
- HMS1921B18
- HMS2095B08
- HMS2235I13
- HMS3371K16
- HMS3656H16
- HMS3712B08
- HMS3885K03
- HMS5081G06
- KUC105648N
- Pharmakon1600-01502003
- ACT07664
- CID:2466
- HY-B0494
- KS-00000XL3
- MSK11363
- ZINC3871797
- Para-butoxyphenylacetohydroxamic acid
- Tox21_110522
- AR-1C7602
- BDBM50015144
- C12-H17-N-O3
- CCG-39191
- CP-1044J3
- EBC-26236
- NCGC00016611-01
- NSC758153
- SBB056991
- 2-(p-butoxyphenyl)-acetohydroxamicaci
- Acide p-butoxyphenylacethydroxamique [French]
- Bufexamac 1.0 mg/ml in Acetonitrile
- N-(4-Butoxyphenylacetyl)hydroxylamine
- SMR000058407
- ACETOHYDROXAMIC ACID, 2-(p-BUTOXYPHENYL)-
- AKOS015895401
- KUC105648N-02
- KUC105648N-03
- Tox21_110522_1
- 2-(p-Butoxyphenyl)acetohydroximic acid
- CAS-2438-72-4
- CP-1044
- CS-2615
- DB13346
- J3.390A
- KSC-10-210
- NSC 758153
- 2-(p-Butoxyphenyl)acetohydoroximic acid
- IDI1_000108
- KSC-390-003
- NCGC00016611-02
- NCGC00016611-03
- NCGC00016611-04
- NCGC00016611-05
- NCGC00016611-06
- NCGC00016611-07
- NCGC00016611-09
- NCGC00016611-10
- NCGC00021813-03
- NCGC00021813-04
- 2-(4-Butoxy-phenyl)-N-hydroxy-acetamide
- 2-(4-Butoxyphenyl)-N-hydroxyacetamide #
- AC-18729
- AJ-46354
- AK117714
- alpha-(p-Butoxyphenyl)-N-hydroxyacetamide
- alpha-(p-Butoxyphenyl)acetohydroxamic acid
- AN-50915
- AS-12207
- LS-13084
- SC-13711
- SY040652
- KSC-285-073-1
- SBI-0051694.P002
- SID:135653741
- AB0005884
- AB00052252
- B1443
- B4179
- FT-0603607
- N-hydroxy2-(4-butoxyphenyl)ethanimidic acid
- NS00000614
- ST24027540
- ST50993888
- SW196831-3
- Bufexamac, 98%, a COX inhibitor - 1G 1g
- C74254
- D01271
- J10267
- K-6542
- AB00052252_19
- AB00052252_20
- A817259
- D002019
- EN300-11686917
- F318152
- Q412699
- SR-01000003067
- I06-0661
- SR-01000003067-3
- SR-01000003067-4
- BRD-K36660044-001-15-0
- BRD-K36660044-001-23-4
- BRD-K36660044-001-24-2
- J3
- Bufexamac, European Pharmacopoeia (EP) Reference Standard
- 219-451-1
- 2438-89-3
- 25044-10-4
- A4Z
- Bufexamac; 4-Butoxy-N-hydroxy-benzeneacetamide; 2-(p-Butoxyphenyl)-acetohydroxamic acid; 2-(p-Butoxyphenyl)acetohydroxamic acid; 4-Butoxyphenylacethydroxamic acid; Anderm; Bufexamic acid; CP 1044J3; Droxarol; Droxaryl; Feximac; Flogocid; Flogocid N plasti; Flogocid N plastigel; Malipuran; Mofenar; Norfemac; Parfenac; Parfenal; p-Butoxyphenylacethydroxamic acid; p-Butoxyphenylacetohydroxamic acid
- J-3